Literature DB >> 10637257

Sex differences in fluorouracil-induced stomatitis.

J A Sloan1, C L Loprinzi, P J Novotny, S Okuno, S Nair, D L Barton.   

Abstract

PURPOSE: A meta-analysis of six North Central Cancer Treatment Group (NCCTG) trials involving patients receiving their first ever fluorouracil (5-FU)-based chemotherapy was undertaken to explore the association of sex with reports of the incidence and severity of stomatitis. PATIENTS AND METHODS: Data were obtained on a total of 731 patients (402 men and 329 women). Comparisons of incidence and severity rates and average stomatitis across sex were performed using standard binomial testing and t tests, respectively. Logistic regression analysis and a weighted analysis using data summarized to study level served as evidence of cross-validation.
RESULTS: Women reported stomatitis both more often and with greater severity than did men. The incidence of any stomatitis for women was 63% versus 52% for men (P =.002). The incidence of severe or very severe stomatitis for men and women was 22% and 12%, respectively (P =. 0006). On average, women reported stomatitis of roughly 0.4 points higher than men on a 0 to 4 ordinal scale (P <.00001). Comparison of results across treatment and placebo arms was carried out to validate the initial findings. Logistic regression modelling further confirmed the results conditional on the presence of a number of potentially confounding covariates. Women were also 11% more likely than men to experience leukopenia of common toxicity criteria grade >/= 1, (70% v 59%, respectively; P <.00001) and grade 3+ (18% v 11%, respectively; P =.004).
CONCLUSION: More women than men reported 5-FU-induced stomatitis. The precise mechanism resulting in different degrees of stomatitis across sex is not evident.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637257     DOI: 10.1200/JCO.2000.18.2.412

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.

Authors:  Roberto Díaz; Jorge Aparicio; Jorge Molina; Laura Palomar; Alejandra Giménez; José Ponce; Angel Segura; José Gómez-Codina
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J L Coenen; J C De Graaf; J R Brouwers
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

3.  The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Authors:  Winson Y Cheung; Qian Shi; Michael O'Connell; James Cassidy; Charles D Blanke; David J Kerr; Jeff Meyers; Eric Van Cutsem; Steven R Alberts; Greg Yothers; Daniel J Sargent
Journal:  Clin Colorectal Cancer       Date:  2013-06-27       Impact factor: 4.481

4.  Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.

Authors:  Elizabeth M Cespedes Feliciano; Valerie S Lee; Carla M Prado; Jeffrey A Meyerhardt; Stacey Alexeeff; Candyce H Kroenke; Jingjie Xiao; Adrienne L Castillo; Bette J Caan
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

5.  Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy.

Authors:  Giulia Fadda; Guglielmo Campus; PierFranca Lugliè
Journal:  BMC Oral Health       Date:  2006-10-18       Impact factor: 2.757

6.  Antioxidant capacity of calendula officinalis flowers extract and prevention of radiation induced oropharyngeal mucositis in patients with head and neck cancers: a randomized controlled clinical study.

Authors:  Neda Babaee; Dariush Moslemi; Mohammad Khalilpour; Fatemeh Vejdani; Yasaman Moghadamnia; Ali Bijani; Mahmoud Baradaran; Mohammad Taghi Kazemi; Asieh Khalilpour; Mahdi Pouramir; Ali Akbar Moghadamnia
Journal:  Daru       Date:  2013-03-07       Impact factor: 3.117

Review 7.  The influence of sex on pharmacokinetics.

Authors:  Janice B Schwartz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

8.  Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.

Authors:  Raafi Ali; Vickie E Baracos; Michael B Sawyer; Laurent Bianchi; Sarah Roberts; Eric Assenat; Caroline Mollevi; Pierre Senesse
Journal:  Cancer Med       Date:  2016-01-27       Impact factor: 4.452

Review 9.  Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem-Literature Review.

Authors:  Aida Kusiak; Barbara AlicjaJereczek-Fossa; Dominika Cichońska; Daniela Alterio
Journal:  Int J Environ Res Public Health       Date:  2020-04-03       Impact factor: 3.390

Review 10.  Dermatologic conditions in women receiving systemic cancer therapy.

Authors:  Michelle N Ferreira; Julie Y Ramseier; Jonathan S Leventhal
Journal:  Int J Womens Dermatol       Date:  2019-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.